Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC ANTITRUST COMPLAINT AGAINST SIX NEW YORK PHARMACEUTICAL ASSOCIATIONS

Executive Summary

FTC ANTITRUST COMPLAINT AGAINST SIX NEW YORK PHARMACEUTICAL ASSOCIATIONS and one individual on April 10 charges that the defendants agreed to boycott the New York State Employees Prescription Plan, the Federal Trade Commission said in a same-day release. The boycott allegedly was designed "to force [the state] to raise reimbursements to pharmacies," FTC said. The commission's complaint asserts that the boycotts cost the state $7 mil. in the 18 months following July 1, 1986, when the plan began. Defendants include the Empire State Pharmaceutical Society, Capital Area Pharmaceutical Society and Alan Kadish, former president of the Pharmaceutical Society of the State of New York (PSSNY). Three other associations -- Long Island Pharmaceutical Society, Pharmaceutical Society of Orange County and Westchester County Pharmaceutical Society -- and PSSNY signed consent agreements to settle the charges. The action is the latest in a series of charges brought against several New York pharmacy chains and associations for anticompetitive activities. A year ago, eight retail chain pharmacies, one trade association and one individual were charged with conspiring to boycott the state prescription drug reimbursement plan ("The Pink Sheet" T&G-11, May 1, 1989). FTC said it "has accepted consent agreements settling the charges against three of the pharmacy chains." Hearings against the remaining seven parties are scheduled for July. In the most recent charges, FTC said, the pharmacy associations agreed "through statements at meetings and other exchanges of information" not to participate in the plan at the proposed reimbursement levels. The New York state insurance plan offered different reimbursement rates to pharmacies in an effort to cut costs. The associations' activities "have unreasonably restrained competition among pharmacists and pharmacies in New York and have injured consumers in three ways: reducing price competition; coercing the state into raising the prices paid to pharmacies under the Employees Prescription Plan; and forcing the state to pay substantial additional sums for prescription drugs under the plan," according to the agency. Under the consent agreements, the four associations agreed not to engage in a number activities which the FTC considers anticompetitive. They vowed not to 1) agree to refuse to enter into any participation agreement; 2) continue a meeting if two parties make statements concerning one or more firms' intentions to withdraw from any participation agreement; 3) communicate to another pharmacist information concerning any other pharmacy's intentions with respect to a participation agreement; and 4) comment to any pharmacist on the desirability or appropriateness of a participation agreement. The consent agreements are for settlement purposes only and are not an admission to violating the law.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel